Benjamin Fand
Urology · Cranford, NJNPI 1134232291
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,459 of the $1,639 with a category attached, or 89.0%. 21 manufacturers reported payments, led by Johnson & Johnson at 25.2% of the total. Reporting peaked in 2019 at $636 and has fallen 97.0% since, to $19 in 2025. That places this record below the midpoint for urology clinicians in NJ, where the typical reported total is $2,095.
Across 93 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$413
- Astellas Pharma US Inc$278
- Dendreon Pharmaceuticals LLC$229
- Bayer$154
- Procept Biorobotics Corporation$106
- AstraZeneca$73
- plus $386 from 15 others
Across 4 payments — averaging $4757.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spectrum Pharmaceuticals Inc.$10K
- Taiho Oncology, Inc.$9K
What the payments were for
- Food & beverage$1,45989%
- Education$18011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $413 |
| Astellas Pharma US Inc | 20 | $278 |
| Dendreon Pharmaceuticals LLC | 11 | $229 |
| Bayer | 8 | $154 |
| Procept Biorobotics Corporation | 2 | $106 |
| AstraZeneca | 5 | $73 |
| Boston Scientific | 4 | $64 |
| AbbVie(2 entities) | 4 | $57 |
| Medtronic | 2 | $31 |
| Pfizer | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $27 |
| Myovant Sciences Inc. | 2 | $27 |
| Olympus America Inc. | 2 | $26 |
| Rochester Medical Corporation | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Amgen | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
| Ambu Inc. | 1 | $12 |
How this compares
$1,639 in reported general payments places this provider in the 40th percentile of 401 urology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 252 | $5,477 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 69 | $1,871 |
| Dutasteride | 43 | $1,060 |
| Finasteride | 52 | $911 |
| Solifenacin Succinate | 11 | $473 |
| Allopurinol | 29 | $367 |
| Oxybutynin Chloride | 13 | $197 |
| Hydrochlorothiazide | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other urology in Cranford
- Mark MillerCranford$14K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.